Current guidelines recommend anticoagulant therapy with vitamin K antagonists, such as warfarin, for just 3-6 months after bioprosthetic valve replacement, even for patients in sinus rhythm.

The phase 3, investigator-initiated ENBALV trial compared the DOAC edoxaban to the vitamin K agonist warfarin in patients who underwent bioprosthetic valve replacement (n=410). Patients were randomly ...

Izumi noted that NOACs have been increasingly used at discharge for patients following bioprosthetic valve replacement “despite this being an off-label use for patients with sinus rhythm.” But ...

NewZNew - Fortis Mohali  Successfully Performs Transcatheter Mitral Valve Replacement on 81-Year-Old Patient: Fortis Hospital ...

Edoxaban was at least as effective as warfarin in preventing thromboembolism after bioprosthetic valve replacement in the ENBALV trial, but the event rate was too low to draw definitive conclusions.

The randomized, multi-center trial included approximately 400 adults in Japan who had bioprosthetic heart valve replacement surgery at the aortic and/or mitral position. Researchers randomized the ...

The randomized, multi-center trial included approximately 400 adults in Japan who had bioprosthetic heart valve replacement surgery at the aortic and/or mitral position. Researchers randomized the ...

Current guidelines recommend anticoagulant therapy for 3-6 months following bioprosthetic valve replacement, including in patients with sinus rhythm, but only warfarin is recommended and approved ...